From Targeted Oncology ... | IDRA Message Board Posts

Idera Pharmaceuticals, Inc

  IDRA website

IDRA   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  1649 of 1653  at  6/8/2020 12:01:48 AM  by

vorlon1966


 In response to msg 1646 by  auh2oman
view thread

Re: From Targeted Oncology ...

“One patient in the ILLUMINATE-206 study had stable disease. Of the 9 patients shown to have progressed on treatment, 6 developed stability or reduction in the size of their injected lesions. There were also 6 patients who showed stability or size reduction in uninjected lesions. In the initial safety cohort of the study, there were no treatment discontinuations due to adverse events (AEs). Also, no grade 4 or 5 AEs were observed in the study.“

Misleading. One had stable disease. None had regression. No complete responses. Did the six others reach stable disease or not? Per recist...no. Beware of double speak. They did or they did not,


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 0     Views: 112
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board






About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...